Why the study?
Does short-term eltrombopag increase platelet counts without accelerating tumor progression in patients with HCC and cirrhosis-related thrombocytopenia?
Population
2 patients with hepatocellular carcinoma (HCC) and cirrhosis-related severe thrombocytopenia
Design
Case_report
Follow-up
2 weeks
Authors
Loading...
May enable ablation in thrombocytopenic HCC without transfusions; hypothesis-generating and requires controlled confirmation.
Does short-term eltrombopag increase platelet counts without accelerating tumor progression in patients with HCC and cirrhosis-related thrombocytopenia?
Short-term eltrombopag may safely increase platelet counts to facilitate invasive procedures like radiofrequency ablation in patients with HCC and cirrhosis without accelerating tumor growth.
Kawaguchi et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: